

## GOOD CLINICAL PRACTICE RECOMMENDATIONS

### CHROMOSOME, FISH & MOLECULAR KARYOTYPING / MICROARRAY ANALYSIS FOR CONSTITUTIONAL INVESTIGATIONS (POSTNATAL, PRENATAL, MISCARRIAGE)

(BeSHG Workgroup on Clinical Genetics, September 2011)

#### 1. POSTNATAL CONSTITUTIONAL

##### **Standard karyotyping (chromosome analysis)**

- Clinically 'clear-cut' chromosomal disorders eg Down syndrome, Turner syndrome, Klinefelter syndrome, ...
- Couples with recurrent miscarriages, Couples with idiopathic infertility/subfertility
- Gamete donors
- Parents (when prenatal karyotype is abnormal)
- Known chromosomal aberration in family/suspicion of a balanced translocation
- Aberration detected with molecular karyotyping, for which a standard karyotype could shed more light on the nature of the aberration eg marker chromosome, unbalanced translocation, ...
- Suspicion of mosaicism in an individual

##### **Molecular karyotyping (various platforms; also known as micro-arrays)**

- Intellectual disability/ autism/ dysmorphism/ Congenital Abnormalities/ neuropsychiatric disorders/neurology/
- Parents of individual with aberration detected with molecular karyotyping
- Refinement of an abnormal karyotype (eg. marker chromosome, deletion, (un)balanced translocation)

**Commenté [G1]:** Should be more precisely defined for the guidelines

**Mis en forme :** Surignage

##### **FISH (fluorescence *in situ* hybridization)**

- Suspected mosaicism in individual (Turner, Klinefelter, Pallister-Killian, ...)
- Parental preparation for Pre-Implantation Genetic Diagnosis (PGD) for chromosome aberration
- Rapid analysis in a neonate with ambiguous genitalia, with suspicion of Down syndrome, trisomy 13/ 18, etc, ...
- Clinically recognizable microdeletion disorders eg VCFS, Williams syndrome, ..
- As an additional tool to (molecular) karyotyping for confirmation and/or further delineation of a chromosomal aberration/ Testing of parents for balanced translocation

**Commenté [G2]:** Is this not a separate item?

##### **Chromosome breakage analysis**

Suspected breakage disorder Eg. Bloom, Fanconi, Nijmegen, ICF, Roberts, AT

## **2. PRENATAL**

### **Standard karyotyping + rapid screening (FISH/MLPA/QF-PCR)**

- Elevated chromosomal aberration risk on 1<sup>st</sup> / 2<sup>nd</sup> trimester maternal blood screening
- Elevated chromosomal aberration risk on combined screening (nuchal translucency, soft markers,+blood)
- Advanced maternal age ( $\geq 35y$ )
- Chromosomal aberration in parent
- Previous pregnancy with chromosomal aberration
- A fetal abnormality on ultrasound
- ICSI pregnancies

Comment: Analysis on amniocytes is preferable to chorionic villi since there is a relative high risk for (confined) placental mosaicism in CVS samples. A chorionic villus sampling is recommended in high risk pregnancies eg echographic fetal abnormality, a parent with chromosome aberration or when molecular/ DNA diagnosis is planned.

### **Molecular karyotyping**

- fetal abnormalities detected on ultrasound
- Refinement of a *de novo* structural chromosome aberration detected on standard karyotype (eg deletion, translocation, inversion, marker chromosome, additional chromosome material)
- Structural (cryptic) chromosomal aberration in sibling/parent

## **3. PREIMPLANTATION GENETIC DIAGNOSIS (PGD)**

### **FISH or molecular karyotyping**

- on blastomeres for chromosome aberration or sex-linked disorder in the parents

## **4. MISCARRIAGE/MORS IN UTERO MATERIAL**

- Molecular karyotyping , or
- Standard karyotyping or
- MLPA/FISH

Commenté [G3]: Rather vague for a guideline...



## **5. REFERENCES**

- Caramins MC et al., A comparison of molecular and cytogenetic techniques for the diagnosis of pregnancy loss. *Genet in Med* 2011;13:46-51.
- European Cytogenetics Association (ECA) Cytogenetic Guidelines and Quality Assurance Appendix A. Indications for Cytogenetic Analysis.
- Hastings RJ et al., Cytogenetic Guidelines and Quality Assurance: a common European framework for quality assessment for constitutional and acquired cytogenetic investigations. *Eur J Hum Genet* 2007; 15:525-527.
- Hochstenbach R et al., Array analysis and karyotyping: workflow consequences based on a retrospective study of 36,325 patients with idiopathic developmental delay in the Netherlands. *Eur J Med Genet* 2009;52:161-169.
- Kolibianakis E et al., Prenatal genetic testing by amniocentesis appears to result in a lower risk of fetal loss than chorionic villus sampling in singleton pregnancies achieved by intracytoplasmic sperm injection. *Fert Steril* 2003;79:374-378.
- Miller DT et al., Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. *Am J Hum Genet* 2010;86:749-764.
- Manning M et al., Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. *Genet in Med* 2010;12:742-745.
- Regier DA et al., Value for Money? Array genomic hybridization for diagnostic testing for genetic causes of intellectual disability. *Am J Hum Genet* 2010;86:765-772.